HELX vs. XPH
Compare and contrast key facts about Franklin Genomic Advancements ETF (HELX) and SPDR S&P Pharmaceuticals ETF (XPH).
HELX and XPH are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. HELX is an actively managed fund by Franklin Templeton. It was launched on Feb 25, 2020. XPH is a passively managed fund by State Street that tracks the performance of the S&P Pharmaceuticals Select Industry Index. It was launched on Jun 19, 2006.
Performance
HELX vs. XPH - Performance Comparison
Loading graphics...
HELX vs. XPH - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
HELX Franklin Genomic Advancements ETF | -8.14% | 26.34% | -5.32% | 1.14% | -37.89% | 9.80% | 85.05% |
XPH SPDR S&P Pharmaceuticals ETF | -2.19% | 31.60% | 4.94% | 2.97% | -9.83% | -10.54% | 25.75% |
Returns By Period
In the year-to-date period, HELX achieves a -8.14% return, which is significantly lower than XPH's -2.19% return.
HELX
- 1D
- 0.90%
- 1M
- -2.17%
- YTD
- -8.14%
- 6M
- 5.21%
- 1Y
- 26.31%
- 3Y*
- 3.29%
- 5Y*
- -5.21%
- 10Y*
- —
XPH
- 1D
- 1.16%
- 1M
- -4.82%
- YTD
- -2.19%
- 6M
- 13.09%
- 1Y
- 30.74%
- 3Y*
- 11.47%
- 5Y*
- 3.03%
- 10Y*
- 3.94%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
HELX vs. XPH - Expense Ratio Comparison
HELX has a 0.50% expense ratio, which is higher than XPH's 0.35% expense ratio.
Return for Risk
HELX vs. XPH — Risk / Return Rank
HELX
XPH
HELX vs. XPH - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Franklin Genomic Advancements ETF (HELX) and SPDR S&P Pharmaceuticals ETF (XPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| HELX | XPH | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.10 | 1.28 | -0.18 |
Sortino ratioReturn per unit of downside risk | 1.63 | 1.80 | -0.17 |
Omega ratioGain probability vs. loss probability | 1.21 | 1.23 | -0.02 |
Calmar ratioReturn relative to maximum drawdown | 1.33 | 1.97 | -0.64 |
Martin ratioReturn relative to average drawdown | 4.32 | 6.54 | -2.23 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| HELX | XPH | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.10 | 1.28 | -0.18 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.22 | 0.15 | -0.36 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.18 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | 0.38 | -0.17 |
Correlation
The correlation between HELX and XPH is 0.70, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
HELX vs. XPH - Dividend Comparison
HELX's dividend yield for the trailing twelve months is around 0.43%, less than XPH's 0.68% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HELX Franklin Genomic Advancements ETF | 0.43% | 0.39% | 0.00% | 0.00% | 0.00% | 0.24% | 0.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XPH SPDR S&P Pharmaceuticals ETF | 0.68% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
Drawdowns
HELX vs. XPH - Drawdown Comparison
The maximum HELX drawdown since its inception was -58.75%, which is greater than XPH's maximum drawdown of -48.03%. Use the drawdown chart below to compare losses from any high point for HELX and XPH.
Loading graphics...
Drawdown Indicators
| HELX | XPH | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -58.75% | -48.03% | -10.72% |
Max Drawdown (1Y)Largest decline over 1 year | -18.01% | -13.15% | -4.86% |
Max Drawdown (5Y)Largest decline over 5 years | -58.75% | -31.63% | -27.12% |
Max Drawdown (10Y)Largest decline over 10 years | — | -35.97% | — |
Current DrawdownCurrent decline from peak | -42.36% | -6.21% | -36.15% |
Average DrawdownAverage peak-to-trough decline | -34.12% | -17.37% | -16.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.56% | 3.96% | +1.60% |
Volatility
HELX vs. XPH - Volatility Comparison
Franklin Genomic Advancements ETF (HELX) and SPDR S&P Pharmaceuticals ETF (XPH) have volatilities of 8.75% and 9.05%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| HELX | XPH | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.75% | 9.05% | -0.30% |
Volatility (6M)Calculated over the trailing 6-month period | 15.40% | 16.40% | -1.00% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.21% | 24.50% | -0.29% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.26% | 20.57% | +3.69% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 27.46% | 22.22% | +5.24% |